Myriad Genetics Reports Fiscal First-Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Myriad Genetics (MYGN) PT Raised to $26 at Morgan Stanley
November 8, 2017 8:43 AM ESTMorgan Stanley raised its price target on Myriad Genetics (NASDAQ: MYGN) to $26.00 (from $24.00) while maintaining a Underweight rating.
... More